Fast & fed in one study (alternative) [Design Issues]

posted by Shuanghe  – Spain, 2020-03-04 17:13 (1916 d 04:59 ago) – Posting: # 21203
Views: 4,673

Dear Helmut

❝ If T shows a substantially lower food effect than R that’s good for the patients. However, if you want to state that in the label/SmPC (“can be taken with or without food”) you have to switch from a generic to a hybrid application. The EMA welcomes that. Whether the additional clinical studies are worth the efforts is another story.


What happens if T is BE to R under fasting and fed but T has much more food effect than R? Will "nice-to-know" become "but-now-I-know-so-you-are-fucked"? What's your experience from regulation perspective?

All the best,
Shuanghe

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,681 registered users;
26 visitors (0 registered, 26 guests [including 14 identified bots]).
Forum time: 23:12 CEST (Europe/Vienna)

EMEA. The European Medicines Evaluation Agency.
The drug regulatory agency of the European Union.
A statistician-free zone.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5